 | Up a level |
2019
Michels, Sebastian, Massuti, Bartomeu, Schildhaus, Hans-Ulrich, Franklin, Jeremy 
ORCID: 0000-0003-1536-0925, Sebastian, Martin, Felip, Enriqueta, Grohe, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S. Y., Bischoff, Helge, Brandts, Christian, Carcereny, Enric, Corral, Jesus, Dingemans, Anne-Marie C., Pereira, Eva, Fassunke, Jana, Fischer, Rieke N., Gardizi, Masyar, Heukamp, Lukas ORCID: 0000-0002-3388-3482, Insa, Amelia, Kron, Anna, Menon, Roopika, Persigehl, Thorsten, Reck, Martin, Riedel, Richard, Rothschild, Sacha I., Scheel, Andreas H., Scheffler, Matthias, Schmalz, Petra, Smit, Egbert F., Limburg, Meike, Provencio, Mariano, Karachaliou, Niki, Merkelbach-Bruse, Sabine, Hellmich, Martin, Nogova, Lucia, Buettner, Reinhard, Rosell, Rafael and Wolf, Juergen
(2019).
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
J. Thorac. Oncol., 14 (7).
S. 1266 - 1277.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1556-1380
2018
Stratmann, Jan A., Michels, Sebastian, Hornetz, Sofia, Christoph, Daniel C., Sackmann, Sandra, Spengler, Werner, Bischoff, Helge, Schaefer, Monica, Alt, Juergen, Mueller, Annette, Laack, Eckart, Kimmich, Martin, Griesinger, Frank and Sebastian, Martin (2018). Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 144 (12). S. 2457 - 2464. NEW YORK: SPRINGER. ISSN 1432-1335
2017
Michels, Sebastian, Gardizi, Masyar, Schmalz, Petra, Thurat, Meike, Pereira, Eva, Sebastian, Martin, Carcereny, Enric, Corral, Jesus, Paz-Ares, Luis, Felip, Enriqueta, Grohe, Christian, Rodriguez Abreu, Delvys, Insa Molla, Amelia, Bischoff, Helge, Reck, Martin, Karachaliou, Niki, Scheel, Andreas, Brandes, Vanessa, Rieke, Fischer, Nogova, Lucia, Scheffler, Matthias, Franklin, Jeremy, Hellmich, Martin, Massuti, Bartomeu, Buettner, Reinhard, Rosell, Rafael and Wolf, Juergen (2017). EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results. J. Thorac. Oncol., 12 (1). S. S379 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380